Changeflow GovPing Healthcare & Life Sciences PFAS, BPA, Pesticides Role in Childhood Obesity...
Routine Notice Added Final

PFAS, BPA, Pesticides Role in Childhood Obesity Studied

Favicon for changeflow.com ClinicalTrials.gov Studies
Detected
Email

Summary

A new clinical trial has been registered on ClinicalTrials.gov (NCT07545174) by NIH to investigate the potential role of environmental chemicals in pediatric obesity. The study will examine per- and polyfluoroalkyl substances (PFAS), bisphenol A (BPA), and non-persistent pesticides as potential contributing factors to the onset of childhood obesity. Participants will undergo blood tests, urine samples, and hair sample collection as part of the study protocol.

“There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 734 changes logged to date.

What changed

NIH has registered a new clinical trial on ClinicalTrials.gov examining environmental chemical exposure and its potential role in pediatric obesity. The study focuses on three categories of chemicals: PFAS compounds (including PFOA, PFOS, PFNA, and PFHxS found in consumer products), BPA used in plastics and resins, and non-persistent pesticides such as organophosphates and polychlorinated biphenyls. The trial will collect biological samples including blood, urine, and hair from pediatric participants to assess potential associations with obesity pathophysiology.

For sponsors and investigators conducting pediatric research or environmental health studies, this trial registration signals continued regulatory and research interest in endocrine-disrupting chemicals as potential obesity drivers. Research institutions studying PFAS, BPA, or pesticide exposure in children may wish to align their protocols with emerging evidence from this study.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Role of the Environment in Pediatric Obesity

N/A NCT07545174 Kind: NA Apr 22, 2026

Abstract

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise.

The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism.

Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products.

Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes.

Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests.

There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

Conditions: Obesity (Disorder)

Interventions: Blood test, Urine sample, Hair sample

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Environmental health research
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Environmental Protection Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!